Business context and reporting period
BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology biotechnology company. This unaudited Form 10-Q covers the three and six months ended January 31, 2024, the company’s fiscal second quarter and first half of fiscal 2024. Financial amounts are in U.S. dollars. The company reported no revenue and continues to devote substantially all efforts to research and development.
Its lead program, Bria-IMT combined with retifanlimab, is being evaluated in a pivotal Phase 3 study for advanced metastatic breast cancer. The filing also describes development of Bria-OTS and a soluble CD80 therapeutic.
Key financial metrics
| Metric | Three months ended Jan. 31, 2024 | Six months ended Jan. 31, 2024 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $8.26 million | $15.11 million |
| General and administrative expense | $1.57 million | $3.22 million |
| Operating loss | $9.83 million | $18.33 million |
| Net loss attributable to BriaCell | $11.29 million | $5.29 million |
| Basic and diluted loss per share | $0.71 | $0.33 |
| Net cash used in operating activities | Not provided for the quarter | $15.01 million |
For the six months, reported net loss was $5.38 million before allocation of $81,978 to non-controlling interests. Net financial income of $12.98 million largely reflected a $12.71 million noncash gain from a lower fair value of warrant liabilities; it offset operating losses and should not be viewed as operating income.
At January 31, 2024, cash and cash equivalents were $6.24 million, current assets $11.74 million, current liabilities $3.92 million, and working capital $7.82 million. Total assets were $12.23 million. The company had a $16.62 million warrant liability and no interest-bearing debt, according to its market-risk disclosure. Shareholders’ deficit was $8.32 million. Common shares outstanding were 15,981,726, unchanged during the six-month period.
Material changes versus comparable periods
- Quarterly R&D expense rose to $8.26 million from $3.05 million a year earlier; six-month R&D expense increased to $15.11 million from $6.31 million. Management attributed the increases chiefly to expanded clinical trials, Phase 3 setup, investigational drug costs, and preclinical and manufacturing work.
- Quarterly operating expenses rose to $9.83 million from $4.49 million. For the six months, operating expenses increased to $18.33 million from $9.89 million.
- Six-month G&A expense declined to $3.22 million from $3.58 million, mainly due to lower share-based compensation and insurance costs.
- Quarterly net loss attributable to BriaCell narrowed to $11.29 million from $11.88 million, while six-month net loss attributable to BriaCell narrowed to $5.29 million from $12.99 million. The six-month comparison was materially affected by the warrant fair-value gain in 2024 versus a fair-value loss in 2023.
- Cash fell by $15.01 million from July 31, 2023, while working capital declined from $25.15 million to $7.82 million. Trade payables increased from $1.12 million to $3.71 million.
- The August 2023 Arrangement spun out certain pipeline assets to BriaPro, in which BriaCell initially retained approximately two-thirds ownership. After quarter-end, BriaCell exercised an option and reported a 51% interest in BC Therapeutics.
Outlook, risks and unusual items
The Phase 3 study was initiated October 3, 2023. The filing describes planned enrollment of 177 patients in the Bria-IMT combination arm, 177 in the physician’s-choice arm, and 50 in a Bria-IMT-alone regimen. Overall survival is the primary endpoint, and Bria-IMT has FDA Fast Track designation. Management cited earlier Phase 2 results, including median overall survival of 13.4 months compared with 6.7–9.8 months reported for similar patients in literature; this is management’s comparison, not a Phase 3 result. The filing provides no financial guidance or forecast.
Management states that operating losses and negative operating cash flows are expected to continue and that additional capital may be needed. The filing says uncertainty about the company’s ability to raise financing raises significant doubt about its ability to continue as a going concern. Management says it intends to seek debt or equity financing, but success and sufficiency are not assured; failure to obtain funds could require reduced or ceased operations.
Other notable items include a $36,000-per-month Philadelphia office and lab lease commitment through August 31, 2024, and up to $241,164 potentially payable to BriaPro in connection with BriaPro warrant shares. Management reported no off-balance-sheet arrangements, no legal proceedings, no material changes to previously disclosed risk factors, effective disclosure controls, and no material change in internal control over financial reporting. The company disclosed foreign-exchange exposure and does not use derivatives to hedge it.
Important facts for investors to verify
- Cash runway and expected timing, amount, and terms of additional financing, given $6.24 million of cash and $15.01 million of operating cash use in the first half.
- Phase 3 enrollment, trial costs, timelines, safety and efficacy updates, and the path to any FDA filing; distinguish clinical outcomes from management’s historical comparisons.
- The size and timing of future R&D spending and whether the reported warrant fair-value gain recurs; it materially affected reported six-month net loss but was noncash.
- Implications of the BriaPro spinout and the post-period BC Therapeutics ownership change for control, consolidation, cash commitments, and potential dilution.
- The cover page marks the company as a shell company, while the filing describes an operating clinical-stage biotech; verify the classification and its context.